Two Sigma Securities’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-24,200
Closed -$361K 3435
2023
Q4
$361K Buy
24,200
+9,700
+67% +$130K ﹤0.01% 1834
2023
Q3
$234K Buy
+14,500
New +$418K ﹤0.01% 2165
2022
Q2
Sell
-6,000
Closed -$497K 2662
2022
Q1
$497K Buy
+6,000
New +$442K 0.02% 1021

Other funds holding NVCR

Two Sigma Securities's NVCR Position: Q1 2026 in Review

Two Sigma Securities sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 20,852 shares — an estimated $270K sold.

Two Sigma Securities first reported a position in NVCR in Q4 2019 and held it in 7 quarters. The position peaked at $1.11M in Q1 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Two Sigma Securities reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 20,852 NovoCure shares in Q1 2026, an estimated $270K.
  • Two Sigma Securities first reported a position in NovoCure in Q4 2019 and held it in 7 quarters.
  • Two Sigma Securities's NovoCure position peaked at $1.11M in Q1 2022.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.